An increasing amount of evidence is accumulating to support the proposal that steroidogenesis can occur by a sesterterpene pathway as well as the cholesterol pathway. Key intermediates on the sesterterpene pathway are 23,24-dinor-5-cholen-3 beta-ol (guneribol) and some of its metabolites, e.g. 23,24-dinor-4-cholen-3-one (guneribone). It has been reported that these intermediates are biosynthesized and converted to steroid hormones by a range of endocrine tissues in vitro. Monitoring the pentafluorobenzyloxime derivatives by negative ion chemical ionization mass spectrometry in the electron capture mode provided evidence for the presence of guneribone in extracts of bovine testicular and human adrenal tumour tissue. Complementary evidence was obtained from gas chromatographic/tandem mass spectrometric data generated on a triple-quadrupole instrument by monitoring daughter ions (in the multiple ion detection, MID mode) of the molecular anion of derivatized guneribone in both standards and tissue extracts. The present findings that sesterterpene pathway intermediates are present as endogenous compounds in tissue extracts, together with the previously reported radiochemical data, give further support to the sesterterpene pathway hypothesis.
[1]
A. Tait.
The conversion of 23,24-dinor-5-cholen-3beta-ol to cortisol by the canine adrenal.
,
1973,
Steroids.
[2]
A. Tait.
The conversion of 23,24-dinor-chol-5-en-3 -ol into steroid hormones.
,
1972,
The Biochemical journal.
[3]
C. Djerassi,et al.
Notes - The Direct Conversion of Steroidal 5-3-Alcohols to 5- and 4-3-Ketones
,
1956
.
[4]
A. Tait,et al.
Adrenal androgen biosynthesis by a sesterpene pathway.
,
1988,
Journal of Steroid Biochemistry.
[5]
K. Eik‐Nes,et al.
Steroid hormone biosynthesis by a sesterterpene pathway in the rat and rabbit testis.
,
1987,
Journal of steroid biochemistry.